olivLaw · US equity research
Cencora, Inc. COR
Wholesale-Drugs, Proprietaries & Druggists' Sundries · SIC 5122 · Vertical: Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
Cencora, Inc. (COR) is one of the largest global pharmaceutical sourcing and distribution companies, with revenue of 321.3 billion USD in fiscal 2025, up 9.3%. In the quarter ended June 30, 2026, revenue rose 5.1% to 84.8 billion USD, and the company announced the acquisition of American Oncology Network at an enterprise value of 2.4 billion USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Cencora, Inc. (COR) stock was 354.00 USD (+3.96% on the day), with market capitalisation 67.6 bn USD, P/E 26.3 on diluted EPS of 13.47 USD over the last 12 months, dividend yield 0.66%, beta -0.02, 52-week range 252.74–374.75 USD. Latest reported quarter (Q3 2026): revenue of 84.8 bn USD (+5.1% YoY), net income of 763.5 m USD (+11.1% YoY), diluted EPS 3.94 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 71.2
- overbought (≥ 70)
- Bollinger (20, 2)
- 318.03 – 350.52
- above the upper band · %B 1.11 · band width 9.7%
- SMA 50 / 200
- 324.63 / 316.94
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 5.24 / 4.20
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +12.4% | −1.1% | +13.5 pp | — |
| 3 months | +11.6% | −0.5% | +12.0 pp | — |
| 6 months | +40.1% | +4.4% | +35.7 pp | — |
| Year to date | +4.8% | +12.3% | −7.5 pp | — |
| 1 year | +2.7% | +13.5% | −10.8 pp | +7.9% |
| 3 years | +81.4% | +76.4% | +5.0 pp | −24.8% |
| 5 years | +177.5% | +63.7% | +113.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 79.1 bn | 81.5 bn | 75.5 bn | 80.7 bn | 83.7 bn | 85.9 bn | 78.4 bn | 84.8 bn |
| Cost of revenue | 76.6 bn | 78.9 bn | 72.4 bn | 77.8 bn | 80.8 bn | 82.9 bn | 74.8 bn | 81.1 bn |
| Gross profit | 2.5 bn | 2.6 bn | 3.1 bn | 2.9 bn | 3.0 bn | 3.1 bn | 3.6 bn | 3.6 bn |
| SG&A | 1.5 bn | 1.5 bn | 1.6 bn | 1.7 bn | 1.7 bn | 1.8 bn | 2.0 bn | 2.1 bn |
| Operating income | 126.6 m | 706.3 m | 1.0 bn | 867.7 m | 18.5 m | 760.4 m | 1.1 bn | 1.1 bn |
| Depreciation & amortisation | — | 278.5 m | 259.8 m | 254.0 m | 258.8 m | 260.4 m | 249.3 m | 269.5 m |
| Pre-tax income | 125.2 m | 620.4 m | 928.7 m | 896.3 m | -187.0 m | 708.6 m | 2.1 bn | 996.4 m |
| Income tax | 117.7 m | 126.7 m | 211.2 m | 206.5 m | 146.0 m | 142.5 m | 459.0 m | 219.7 m |
| Net income | 3.4 m | 488.6 m | 717.9 m | 687.4 m | -339.7 m | 559.6 m | 1.6 bn | 763.5 m |
| Diluted EPS | 0.02 ≈ | 2.50 | 3.68 | 3.52 | -1.74 ≈ | 2.87 | 8.40 | 3.94 |
| Operating cash flow | 1.0 bn | -2.7 bn | 3.4 bn ≈ | 109.2 m ≈ | 3.1 bn | -2.3 bn | 1.3 bn ≈ | 2.7 bn ≈ |
| Capex | 182.3 m | 105.9 m | 129.1 m ≈ | 183.2 m ≈ | 249.8 m | 119.4 m | 165.6 m ≈ | 226.0 m ≈ |
| Dividends paid | 100.9 m | 110.9 m | 111.2 m ≈ | 107.5 m ≈ | 107.5 m | 126.5 m | 117.5 m ≈ | 116.6 m ≈ |
| Share repurchases | 505.0 m | 385.4 m | 50.0 m ≈ | 0 ≈ | 71.0 k | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 74 percentile of its own 39-quarter history (min 11.0, median 20.6, max 66.1; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 167.9 bn | 179.6 bn | 189.9 bn | 214.0 bn | 238.6 bn | 262.2 bn | 294.0 bn | 321.3 bn |
| Revenue YoY | +9.7% | +6.9% | +5.7% | +12.7% | +11.5% | +9.9% | +12.1% | +9.3% |
| Net income | 1.7 bn | 855.4 m | -3.4 bn | 1.5 bn | 1.7 bn | 1.7 bn | 1.5 bn | 1.6 bn |
| Net income YoY | +355.0% | −48.4% | −498.5% | unavailable | +10.3% | +2.7% | −13.5% | +3.0% |
| Diluted EPS | 7.53 | 4.04 | -16.65 | 7.39 | 8.04 | 8.53 | 7.53 | 7.96 |
| Diluted EPS YoY | +359.1% | −46.3% | −512.1% | unavailable | +8.8% | +6.1% | −11.7% | +5.7% |
| net % | 1.0% | 0.5% | -1.8% | 0.7% | 0.7% | 0.7% | 0.5% | 0.5% |
| Free cash flow | 1.1 bn | 2.0 bn | 1.8 bn | 2.2 bn | 2.2 bn | 3.5 bn | 3.0 bn | 3.2 bn |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 30 Sept 2025
- Cash
- 4.4 bn USD
- Financial debt
- 7.7 bn USD
- Net debt
- 3.3 bn USD
- Equity
- 1.7 bn USD
- Total assets
- 76.6 bn USD
- Debt / equity
- 4.38x
- Current ratio
- 0.90x
- ROE
- 122.7%
- ROA
- 2.2%
- FCF margin
- 1.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 189.9 bn | 214.0 bn | 238.6 bn | 262.2 bn | 294.0 bn | 321.3 bn | SEC (XBRL)· 25 Nov 2025verified |
| Cost of revenue | 184.7 bn | 207.0 bn | 230.3 bn | 253.2 bn | 284.0 bn | 309.9 bn | SEC (XBRL)· 25 Nov 2025verified |
| Gross profit | 5.2 bn | 6.9 bn | 8.3 bn | 9.0 bn | 9.9 bn | 11.5 bn | SEC (XBRL)· 25 Nov 2025verified |
| SG&A | 2.8 bn | 3.6 bn | 4.8 bn | 5.3 bn | 5.7 bn | 6.5 bn | SEC (XBRL)· 25 Nov 2025verified |
| Operating income | -5.1 bn | 2.4 bn | 2.4 bn | 2.3 bn | 2.2 bn | 2.6 bn | SEC (XBRL)· 25 Nov 2025verified |
| Depreciation & amortisation | 391.1 m | 505.2 m | 693.9 m | 963.9 m | 1.1 bn | 1.1 bn | SEC (XBRL)· 25 Nov 2025verified |
| EBITDA | -4.7 bn ≈ | 2.9 bn ≈ | 3.1 bn ≈ | 3.3 bn ≈ | 3.3 bn ≈ | 3.7 bn ≈ | SEC (XBRL)· 25 Nov 2025derived |
| Pre-tax income | -5.3 bn | 2.2 bn | 2.2 bn | 2.2 bn | 2.0 bn | 2.3 bn | SEC (XBRL)· 25 Nov 2025verified |
| Income tax | -1.9 bn | 677.3 m | 516.5 m | 428.3 m | 484.7 m | 690.5 m | SEC (XBRL)· 25 Nov 2025verified |
| Net income | -3.4 bn | 1.5 bn | 1.7 bn | 1.7 bn | 1.5 bn | 1.6 bn | SEC (XBRL)· 25 Nov 2025verified |
| Diluted EPS | -16.65 | 7.39 | 8.04 | 8.53 | 7.53 | 7.96 | SEC (XBRL)· 25 Nov 2025verified |
| Weighted average diluted shares | 204.8 m | 208.5 m | 211.2 m | 204.6 m | 200.3 m | 195.2 m | SEC (XBRL)· 25 Nov 2025verified |
| Dividend per share | 1.66 | 1.76 | 1.84 | 1.94 | 2.04 | 2.20 | SEC (XBRL)· 25 Nov 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 4.6 bn | 2.5 bn | 3.4 bn | 2.6 bn | 3.1 bn | 4.4 bn | SEC (XBRL)· 25 Nov 2025verified |
| Receivables | 13.8 bn | 18.2 bn | 18.5 bn | 20.9 bn | 23.9 bn | 25.2 bn | SEC (XBRL)· 25 Nov 2025verified |
| Inventories | 12.6 bn | 15.4 bn | 15.6 bn | 17.5 bn | 19.0 bn | 20.5 bn | SEC (XBRL)· 25 Nov 2025verified |
| Current assets | 33.1 bn | 38.8 bn | 39.6 bn | 42.8 bn | 47.7 bn | 52.2 bn | SEC (XBRL)· 25 Nov 2025verified |
| Property, plant & equipment, net | 1.5 bn | 2.2 bn | 2.1 bn | 2.1 bn | 2.2 bn | 2.5 bn | SEC (XBRL)· 25 Nov 2025verified |
| Goodwill | 6.7 bn | 9.0 bn | 8.5 bn | 9.6 bn | 9.3 bn | 13.7 bn | SEC (XBRL)· 25 Nov 2025verified |
| Intangibles (excl. goodwill) | 1.9 bn | 5.3 bn | 4.3 bn | 4.4 bn | 4.0 bn | 3.8 bn | SEC (XBRL)· 25 Nov 2025verified |
| Total assets | 44.3 bn | 57.3 bn | 56.6 bn | 62.6 bn | 67.1 bn | 76.6 bn | SEC (XBRL)· 25 Nov 2025verified |
| Accounts payable | 31.7 bn | 38.0 bn | 40.2 bn | 45.8 bn | 50.9 bn | 54.7 bn | SEC (XBRL)· 25 Nov 2025verified |
| Short-term debt | 501.3 m | 300.2 m | 1.1 bn | 641.3 m | 576.3 m | 117.8 m | SEC (XBRL)· 25 Nov 2025verified |
| Long-term debt | 3.6 bn | 6.4 bn | 4.6 bn | 4.1 bn | 3.8 bn | 7.5 bn | SEC (XBRL)· 25 Nov 2025verified |
| Current liabilities | 33.9 bn | 41.4 bn | 43.5 bn | 48.8 bn | 54.3 bn | 57.8 bn | SEC (XBRL)· 25 Nov 2025verified |
| Equity | -839.6 m | 584.4 m | 71.3 m | 666.3 m | 786.7 m | 1.7 bn | SEC (XBRL)· 25 Nov 2025verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.2 bn | 2.7 bn | 2.7 bn | 3.9 bn | 3.5 bn | 3.9 bn | SEC (XBRL)· 25 Nov 2025verified |
| Capex | 369.7 m | 438.2 m | 496.3 m | 458.4 m | 487.2 m | 668.0 m | SEC (XBRL)· 25 Nov 2025verified |
| Free cash flow | 1.8 bn ≈ | 2.2 bn ≈ | 2.2 bn ≈ | 3.5 bn ≈ | 3.0 bn ≈ | 3.2 bn ≈ | SEC (XBRL)· 25 Nov 2025derived |
| Investing cash flow | -379.9 m | -6.1 bn | -368.4 m | -2.6 bn | -618.1 m | -5.0 bn | SEC (XBRL)· 25 Nov 2025verified |
| Financing cash flow | -603.6 m | 2.0 bn | -1.8 bn | -2.2 bn | -2.3 bn | 2.2 bn | SEC (XBRL)· 25 Nov 2025verified |
| Dividends paid | 343.6 m | 366.6 m | 391.7 m | 398.8 m | 416.2 m | 437.1 m | SEC (XBRL)· 25 Nov 2025verified |
| Share repurchases | 420.4 m | 82.2 m | 483.7 m | 1.2 bn | 1.5 bn | 435.5 m | SEC (XBRL)· 25 Nov 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 51 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 67.6 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation28
- Returns51
- Quality93
- Balance sheet40
- Growth43
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 88.11 – 429.34 USD.
Methods computed but outside the aggregate range: Dividend discount (DDM) (a small share of earnings is paid as dividends (capital returns through buybacks): the dividend model does not describe the value and stays outside the aggregate).
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDA88.11 – 310.22 (Mid 198.93)4 companies used · median multiple 11.5x · quartiles 6.3x – 16.7xCAH, HLF, MCK, NUS
- Peers: P/E246.52 – 429.34 (Mid 370.64)3 companies used · median multiple 27.5x · quartiles 18.3x – 31.9xCAH, HLF, MCK
- Dividend discount (DDM)outside the aggregate28.91 – 38.88 (Mid 33.16)a small share of earnings is paid as dividends (capital returns through buybacks): the dividend model does not describe the value and stays outside the aggregate
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 51/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 21.9% | 100 (on a fixed band) | 11% |
| Net margin · Quality | 0.8% | 75 (vs peers) | 7% |
| FCF conversion · Quality | 154.7% | 100 (on a fixed band) | 7% |
| Revenue CAGR 3Y · Growth | 10.4% | 87 (on a fixed band) | 9% |
| EPS CAGR 3Y · Growth | -0.3% | 0 (on a fixed band) | 9% |
| Net debt / EBITDA · Balance sheet | 2.2x | 52 (on a fixed band) | 11% |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 0.9x | 11 (on a fixed band) | 4% |
| P/E (TTM) · Valuation | 26.3x | 17 (on a fixed band) | 11% |
| EV/EBITDA · Valuation | 18.7x | 0 (on a fixed band) | 11% |
| FCF yield · Valuation | 6.0% | 75 (on a fixed band) | 9% |
| Shareholder yield (distributions) · Returns | 1.3% | 19 (on a fixed band) | 7% |
| Payout ratio (FCF) · Returns | 11.5% | 100 (on a fixed band) | 4% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth43/100 · 2/2 factors with a value
- Quality93/100 · 3/3 factors with a value
- Returns51/100 · 2/2 factors with a value
- Valuation28/100 · 3/3 factors with a value
Memo
CENCORA, INC. (COR). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 321.3 bn USD in 2025; YoY growth 9.3%; net margin 0.8%; ROE 104.3%; net debt/EBITDA 2.2x.
The estimated value range is 167.32–369.78 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 284.79 USD, the price of 354.00 USD leaves a potential of -19.6% (value / price − 1) and a margin of safety of -24.3% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 51/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 21.9%
- Net margin: 0.8%
- FCF conversion: 154.7%
- Revenue CAGR 3Y: 10.4%
- FCF yield: 6.0%
- Payout ratio (FCF): 11.5%
What contradicts it
- EPS CAGR 3Y: -0.3%
- Current ratio: 0.9x
- P/E (TTM): 26.3x
- EV/EBITDA: 18.7x
- Shareholder yield (distributions): 1.3%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): Interest coverage.
Versus the vertical median
Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122) · same industry (4-digit SIC) · compared with 8 companies
The size band was not applied: too few companies would have remained; the vertical includes much smaller or larger companies.
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| MCKMcKESSON CORPORATION | 123.5 bn | 27.5 | — | 1.1% | +12.4% | +21% / +127% |
| CORCencora, Inc. | 67.6 bn | 26.3 | 104.3% | 0.8% | +9.3% | +3% / +81% |
| CAHCardinal Health, Inc. | 60.9 bn | 36.2 | — | 0.7% | +14.2% | +23% / +145% |
| HLFHerbalife Ltd. | 1.6 bn | 9.1 | — | 3.4% | +0.9% | +20% / +19% |
| NUSNu Skin Enterprises, Inc. | 242.9 m | — | -32.5% | -15.7% | −14.3% | −50% / −71% |
| COSMCosmos Health Inc. | 33.0 m | — | -104.0% | -33.1% | +19.9% | −49% / −69% |
| HKPDCellyan Biotechnology Co., Ltd | 30.2 m | — | -0.6% | -0.1% | +21.7% | +87% / unavailable |
| ESYNHwh International Inc. | 11.6 m | — | -88.9% | -680.0% | −30.8% | −4% / −97% |
| MEDSDataMeds AI, Inc. | 4.6 m | — | — | -1,100.3% | +28.7% | −95% / unavailable |
1- and 3-year price returns: for COR from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 226.40 Total return -35% · Per year -35% | 399.17 Total return 14% · Per year 14% | 599.79 Total return 70% · Per year 70% |
| 3 years | 246.71 Total return -29% · Per year -11% | 486.82 Total return 40% · Per year 12% | 799.22 Total return 129% · Per year 32% |
| 5 years | 268.85 Total return -21% · Per year -5% | 593.71 Total return 72% · Per year 11% | 1,064.97 Total return 207% · Per year 25% |
- Exit P/E± 121.70
- Net margin± 85.19
- Annual revenue growth± 66.17
- Annual dilution± 7.16
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 21 Oct 2026; since then the company filed 8-K (04 Nov 2026 · results).
In brief
Cencora, Inc. (COR) is one of the largest global pharmaceutical sourcing and distribution companies, with revenue of 321.3 billion USD in fiscal 2025, up 9.3% 1. In the quarter ended June 30, 2026, revenue rose 5.1% to 84.8 billion USD 2, and the company announced the acquisition of American Oncology Network at an enterprise value of 2.4 billion USD 3.
SWOT
Strengths
- A leading position in global pharmaceutical distribution, with very large revenue and an extensive network of distribution centers 1.
- Steady revenue growth in both reportable segments, supported by unit volumes and specialty activity 12.
- Value-added services for customers and manufacturers that strengthen long-term commercial relationships 1.
Weaknesses
- High dependence on a few large customers and group purchasing organizations, so losing one contract could have a significant impact 1.
- Very thin gross margins in U.S. distribution, especially as lower-margin products grow in mix 1.
- Goodwill impairment and acquisition and integration costs were high in fiscal 2025 1.
Opportunities
- Expansion in community oncology through the American Oncology Network acquisition could strengthen the services platform 3.
- Greater use of generics and biosimilars could improve long-term profitability 1.
- Specialty activities and manufacturer services, which carry higher margins, could become a more important growth source 1.
Threats
- Losing or renegotiating major customer contracts on weaker terms could affect revenue and cash flow 1.
- Tariffs and other protectionist measures could raise costs or disrupt supply of pharmaceutical products 1.
- Changes in strategy under the new owners of Walgreens Boots Alliance could alter commercial agreements with the company 1.
Risks
- Customer concentrationhigh
A small number of customers generates a large share of revenue and receivables, so losing one contract could materially reduce results 1.
- Walgreens and Boots relationshiphigh
New owners of Walgreens could seek changes to agreements, and planned pharmacy closures could reduce distributed volumes 1.
- Acquisition integration riskmedium
Integrating RCA, OneOncology and AON could prove harder and costlier than expected, with regulatory and liability risks for assumed obligations 13.
- Geopolitical and trade risksmedium
International operations expose the company to inflation, currency swings and tariff measures that are hard to predict 1.
- Compliance and litigation costslow
Opioid-related litigation and other proceedings can generate expenses and reputational harm, even though some costs declined in fiscal 2025 1.
Investment thesis
What would need to be true (bull case)
- If volume growth and specialty activity continue, the company could sustain revenue and operating profit growth, supported by its adjusted fiscal 2026 guidance 23.
- If the American Oncology Network acquisition integrates well, it could strengthen the community oncology position and contribute to results after two years, according to the company's expectations 3.
- If generic and biosimilar use grows, margins on those products could improve long-term distribution profitability 1.
What would break the thesis
- If a large customer chooses to reduce volumes or renegotiate contracts, revenue could fall materially given the high customer concentration 1.
- Growth in low-margin products such as GLP-1 drugs could compress gross margins if the trend continues 12.
- Costly acquisitions and integration risks could reduce returns on investment and weigh on medium-term financial results 13.
What to watch
- Fiscal 2027 outlook, to be discussed on the fourth quarter fiscal 2026 earnings callQ4 2026
- Completion of the American Oncology Network acquisition and regulatory clearance2027
- Evolution of the Walgreens and Boots relationship after ownership changes2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 21 Oct 2026; since then the company filed 8-K (04 Nov 2026 · results).
The business
Cencora broadly distributes brand-name, specialty and generic medicines, over-the-counter products and home healthcare supplies to hospitals, pharmacies, clinics and physicians in the United States and selected global markets 1. It also offers related services such as data analytics, regulatory consulting, niche premium logistics and inventory management to providers and manufacturers 1. The business is organized into two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions 1.
The strategy aims to drive efficiency in core distribution in the U.S. and abroad while investing in higher-margin, faster-growing activities such as specialty therapies and manufacturer services 1. The January 2025 acquisition of Retina Consultants of America broadened its community specialty network 1, and from the first quarter of fiscal 2026 it reports under a new structure in which several businesses sit in Other and are exploring strategic alternatives 1.
Customer concentration is high: Walgreens and Boots together accounted for about 25% of fiscal 2025 revenue, and Evernorth Health Services for about 13% 1. Relationships with large customers and group purchasing organizations are central, and losing or renewing them on less favorable terms could affect results 1.
Market context
The company cites an expected U.S. pharmaceutical sales compound annual growth rate of about 8.4% from 2024 through 2029, partly dependent on manufacturer price increases 1. Generics account for about 90% of U.S. prescription volume, and pharmaceuticals about 9% of overall healthcare costs 1.
The market is shaped by pricing pressure, patent expirations, customer consolidation and tariff policy, which could affect costs and supply 1. Results are also sensitive to currency rates, Turkish inflation and European economic conditions 1.
Trends
- GLP-1 diabetes and weight-loss drugsmixed
Rising GLP-1 sales have lifted revenue, but these products carry lower gross margins, which could limit profitability gains if demand stays strong 12.
- Generics and biosimilarsmixed
Greater use of generics and biosimilars can offer better gross margin opportunities, though lower prices reduce revenue growth, and patent expirations could accelerate this shift 1.
- Consolidation in community oncologytailwind
The American Oncology Network deal and earlier investments in OneOncology and RCA point to expansion in community care services, which could support growth if integration succeeds 13.
- Tariff and geopolitical pressuresheadwind
Proposed tariffs and shifting trade policy could raise costs or disrupt supply, particularly for imported products, and inflation in Turkey remains a cost factor 1.
Competitive position
The company operates in a concentrated pharmaceutical distribution market where a few large players compete on volume, operating cost and customer services. The supplied source texts do not name competitors, and comparisons are limited to the company's own claim of having one of the lowest operating cost structures in the sector 1.
Advantages cited include a broad distribution center network, warehouse automation, and provider programs such as Good Neighbor Pharmacy and Elevate Provider Network 1. Industry competition is noted as a factor that could influence future revenue 1.
- Competitors named in the supplied sources
The supplied sources do not name competitors, so no tickers are listed.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report04 Nov 2026Regulation FD disclosure · Financial statements and exhibits
- Current report04 Nov 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Current report21 Oct 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Current report25 Sept 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report14 Aug 2026Departure or appointment of officers
- Current report12 Aug 2026Regulation FD disclosure
- Quarterly report05 Aug 2026
- Current report05 Aug 2026Material agreement · Creation of a direct financial obligation · Financial statements and exhibits
- Current report05 Aug 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Current report15 Jun 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-09-30 · SEC / Cencora, Inc. · 25 Nov 2025
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Cencora, Inc. · 05 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Cencora, Inc. · 21 Oct 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.